NextCure, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including Antibody-Drug Conjugates (ADCs), antibodies, and proteins. Co. focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidates include NC410 and LNCB74. Its Clinical Oncology Programs are NC525 and NC318. We show 24 historical shares outstanding datapoints in our NXTC shares outstanding history coverage, used to compute NXTC market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NXTC market cap history over the course of time is important for investors
interested in comparing NXTC's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NXTC versus a peer is one thing; comparing
NXTC market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NXTC can fluctuate over the course of history.
With this page we aim to empower investors researching NXTC by allowing them to research the NXTC market cap history. |
Free NXTC Email Alerts:
Video: The Importance of Market Cap
